Uptrend Under Pressure 100
Institutional selling is building — 7 distribution days in the last 25 sessions. Severe risk · 100/100 · 7 distribution days (SPY) Oct 26 Full briefing →
View
Simple research view

BDX · Becton, Dickinson and Company

$196.39 -1.27% Oct 26 close
Detected setup watchlist_candidate · Setup Score 0/100

Stand aside — setup invalidated

Setup score 0, but distribution days reach 5 or more — stand aside until the condition resets.

Ask about BDX

Switch to Advanced for indicator panels, raw grades, provenance, drawing tools, and full technical tables.

$BDX

Becton, Dickinson and Company

Becton, Dickinson and Company is a large-cap Medical Specialties company in the Health Technology sector with a market cap of $53B.

Health Technology Medical Specialties stock Stage 2 · Advancing Base 1
$196.39 latest close
Market Structure
Trend structure: range
Latest event: structure_shift (bullish)
Support 151.97–153.74 · 6 touches · strong
Support 158.20–159.49 · 4 touches · moderate
Support 186.63–188.04 · 4 touches · moderate
Support 195.63–196.36 · 4 touches · moderate
Support 162.29–163.44 · 3 touches · moderate
Verdict · setup score 0/100 · data Oct 26 close · latest session

Stand aside — setup invalidated

Setup score 0, but distribution days reach 5 or more — stand aside until the condition resets.

Recent price action · daily
$180$200AugSepOct$196

What would change this verdict

What needs to turn for this to become buyable — the top failing checks across the legend council:

  • Minervini 1.2 150-day MA > 200-day MA — MA150 $164.78 vs MA200 $169.85
  • Minervini 1.8 RS rank ≥ 70 (prefer ≥ 85) — RS rank 69
  • O'Neil C: Quarterly EPS acceleration ≥ 25% — -0.3% QoQ
  • O'Neil L: RS rank ≥ 80 (IBD leadership) — RS rank 69
  • Weinstein Volume expansion above average — Volume ratio 0.98x
  • Weinstein 30-week MA trending upward
Minority view — the council disagrees here
  • Minervini: avoid Trend-template read: fails 150-day MA > 200-day MA.
  • O'Neil: avoid CANSLIM read: fails C: Quarterly EPS acceleration ≥ 25%.
  • Weinstein: watch Stage-analysis read: Stage 2 is present; 2 supporting checks need improvement.
57 Neutral
Legend Score · rates the stock Neutral (57/100) — held back by eps growth

Our proprietary 0-100 rating — the answer to Wall Street's black-box scores. Five pillars, each computed from real scan data, each explained below in plain English.

  • Relative Strength (25%) 69
  • Trend Template (25%) 62
  • Institutional Footprint (20%) 64
  • EPS Growth (15%) 30
  • Quality (SMR-like) (15%) 44

RS rank 69: above-average strength. Trend template 5/8: mixed — some uptrend elements, some missing. Institutional score 64: mild accumulation. EPS -0% last quarter — no earnings momentum. Quality 44: weak fundamentals (sales growth 30, return on equity 40, leverage 100). Updated 2026-10-27.

Earnings

Pre-earnings setup

Next earnings Monday, November 2, 2026 After market close Exact clock time not supplied by source

Deterministic evidence

BDX-1.27%
Sector proxy · XLV+0.00%
Broad market · SPY+0.71%
Same completed session window ending 2026-10-26. BDX was -1.27 points vs XLV. -1.98 points vs SPY.
CatalystPending Stock reactionNegative Sector reactionWeak Opening surgePending Event riskEarnings-driven

Session internals Mixed

Rule: direction and internals disagree — it met neither the strong nor the weak rule. Judged on internals, not on the size of the move.

Vs prior close-1.27% From the open-0.88% Range position40% GapNo gap
QQQ confirmationDiverging (+1.11%) SMH confirmationDiverging (+2.74%)
Short-term conviction -2 points.
  • QQQ, SMH moved against the stock — no index confirmation.
  • A sourced earnings report is still pending inside the risk window; ordinary technical conviction is reduced until it is out.
Price bars, sourced event fields, and benchmark math only. This can adjust displayed short-term conviction; it does not change the stored scanner score or readiness.

Ask a Legend to interpret this evidence → Commentary only — never scanner evidence or a sizing recommendation.

Price $196.39 -1.3% Oct 26 close
52W High $213.08 7.8% below high
Wks Since High 36w
Base Depth 33.0% 34.2% today
RS Rank 32 percentile of scan
SMA 50 $185.63
Avg Vol 1,678,835
Rel Vol (Oct 26) 0.98× 0.90× on up days
More stats
52W Low $140.11
Tight Wks 0
Base B1
SMA 200 $169.85
RS Line vs High -15.8%
RS Line Slope +7.8% ▲
Group Rank #21/66
ADR% 2.1%
ATR(14) $4.12 (2.1%)
Vol Pace (live) N/A
A/D Days 14A / 14D
A/D Rating C
VDU Bars 0/10 d
Power Trend 8d
Earnings in 6d
Position in 52-week range 77thpercentile of the 52-week range
$140.11low
$213.08high

BDX Chart

Interactive price, volume, RS, RSI, and MACD charts are available after sign in.

Create a free account to load the full interactive chart for BDX.

Create Free Account

Technical Analysis Report Card

$BDX · $196.39 · as of 2026-10-26 · multi-factor read
98
/ 100
Technicals 98/100
Reference read from price & volume only — the verdict at the top of the page decides the action.

Trend · Daily / Weekly / Monthly

Daily ▲ Uptrend
Weekly ▲ Uptrend
Monthly ▲ Uptrend

Moving Averages

50-day$185.63 ↑
100-day$171.72 ↑
200-day$169.85 ↑
Bullish (50 > 200)

RSI (14)

Reading63.5 · Bullish

Bullish momentum — comfortably in buyer territory.

MACD (12/26/9)

StateBullish
Histogram+1.175

Bullish — MACD above its signal line and above zero. Histogram contracting.

Bollinger Bands (20,2)

%B / Width80% · 15.7%

Near the upper band — buyers in control.

Volume · Buyer vs Seller

Up/Down vol0.9 · Neutral
Rel volume0.98×
Pocket pivots · 10d0
5d vs 50d vol76%
Heavy vol up / down0 / 0

Balanced — up/down volume is roughly even; no clear hand. Recent volume is easing versus its baseline.

Support & Resistance

R · $213.0852-week high
Price · $196.39now
S · $175.45swing level
S · $152.79swing level
S · $148.23swing level

Fibonacci · Uptrend swing

23.6%$186.23
38.2%$177.41
50.0%$170.29
61.8%$163.17
78.6%$153.03

Retracement support zones measured from the recent swing low up to the high.

The verdict is free. The trade plan is Pro.
Unlock the exact entry, stop-loss, profit target, and reward-to-risk for BDX — plus the full 500+ symbol scanner and Ask-the-Legends chat.
Start your 7-day free trial →
Daily uptrendWeekly uptrendMonthly uptrendAbove 200-day MA50/200 bullish
Want this read in a legend's voice? Ask a Legend about BDX
Generic technical analysis generated mechanically from price & volume — educational research only, not financial advice or a personalized recommendation. Levels are illustrative; confirm on your own chart. New to these terms? →
Legend Verdicts 6 methodology checks

Who would consider this setup, why it qualifies, and what blocks it — calculated from the same deterministic methodology rules used across Legend AI.
How to read the numbers: the setup score (0/100, in the verdict band) rates this trade setup. Each legend's A–D grade rates the same setup against that legend's own checklist — so a high score next to a C grade is not a contradiction. The setup can be strong without fitting that legend's style. When the council disagrees, the verdict band breaks the tie.

Council consensus: 6 of 9 legends are Watching — building, not yet a confirmed buy.
Minervini Avoid D Trend-template read: fails 150-day MA > 200-day MA.
Passing evidence
1.1 Price > 150-day MA AND 200-day MAPrice $196.39, MA150 $164.78, MA200 $169.85
1.4 50-day MA > 150-day MA AND 200-day MAMA50 $185.63, MA150 $164.78, MA200 $169.85
Failing evidence
1.2 150-day MA > 200-day MAMA150 $164.78 vs MA200 $169.85
1.8 RS rank ≥ 70 (prefer ≥ 85)RS rank 69
5/10 checks
O'Neil Avoid D CANSLIM read: fails C: Quarterly EPS acceleration ≥ 25%.
Passing evidence
N: Near 52-week high or RS line new high7.8% below high | RS line new high: False
S: Base tightness (ATR% ≤ 4.5%)ATR% 2.10%
Failing evidence
C: Quarterly EPS acceleration ≥ 25%-0.3% QoQ
L: RS rank ≥ 80 (IBD leadership)RS rank 69
2/8 checks
Weinstein Watch C Stage-analysis read: Stage 2 is present; 2 supporting checks need improvement.

mediumStage 2 uptrend in progress — hold as long as price stays above the 30-week moving average.

Passing evidence
Stage 2 (Advancing phase) confirmedStage 2 (Advancing)
Price above 30-week MA (200-day proxy)Price $196.39 vs MA200 $169.85
Failing evidence
Volume expansion above averageVolume ratio 0.98x
30-week MA trending upwardData unavailable
4/6 checks
dennis Watch C Turtle read: no breakout yet. Price is pressing the 20-day high. The system waits for the print; it never anticipates.
Passing evidence
No breakdown below the 20-day channel20-day low $175.71
Volatility-unit sizing (1N ≈ 1% of equity)1N = $4.12 (2.10% of price); the Turtles size 1 unit so a 1N move ≈ 1% of equity, making the 2N stop ≈ 2% equity risk
Failing evidence
S1: 20-day Donchian breakoutNot confirmed
S2: 55-day Donchian breakoutNot confirmed
5/7 checks
zanger Avoid D Zanger read: a hard gate is broken — either the pattern is not one of his six, or the entry is more than 5% past the breakout. He would not touch this.
Passing evidence
Partial-profit plan: sell 20-30% at +15-20%Scale 20-30% at $225.85-$235.67; trail the rest
Trail on the 10/20-day MA10-day MA $193.64 · 20-day MA $187.44 — exit the remainder on a close below the trail
Failing evidence
Named Zanger pattern onlywatchlist_candidate is not one of Zanger's six
Not extended (≤5% above the breakout point)Data unavailable
3/6 checks
zweig Watch D Zweig read: part of his screen passes but not all: EPS growth above the market (≥15% QoQ); Insider buying; Price strength (RS ≥ 70) — wait for the full growth screen before treating this as a Zweig setup.
Passing evidence
Reasonable price for the growth (P/E ≤ 35)Trailing P/E 33.7x — no PEG or forward P/E stored
Breadth momentum: 10-day A/D ratio10-day A/D 1.17 (2025 adv / 1725 dec) — participation expanding
Failing evidence
EPS growth above the market (≥15% QoQ)-0.3% QoQ — Zweig wants growth above the S&P average
Insider buyingNo insider buying flagged
3/8 checks
Livermore Watch B Pivotal-point read: constructive evidence is present, but relative strength is unresolved.
Passing evidence
Price$196.39
Distance from 52-week high7.8% below high
Failing evidence
Relative strengthRS 69
Volume vs average0.98x
3/6 checks
Darvas Watch B Box-theory read: constructive evidence is present, but relative strength is unresolved.

mediumBuilding the top of the box (7.8% from 52W high) — watch for a box breakout with volume expansion.

Passing evidence
Price$196.39
Distance from 52-week high7.8% below high
Failing evidence
Relative strengthRS 69
Volume vs average0.98x
3/6 checks
Wyckoff Watch B Supply-and-demand read: constructive evidence is present, but relative strength is unresolved.
Passing evidence
Price$196.39
Distance from 52-week high7.8% below high
Failing evidence
Relative strengthRS 69
Volume vs average0.98x
3/6 checks
Base & Breakout
Breakout follow-through

No active breakout tracked — Legend AI monitors daily for pivot-point breaks. What's a breakout?

RS Line vs SPY 52-week relative strength · blue = RS line · dashed = MA50 · dot = NH ▲ Rising
94RS Line (52W)
Accumulation / Distribution last 65 sessions · green = acc on high vol · red = dist on high vol Net +3 C
A: 17 D: 14 Net: +365 sessions
Minervini · Grade Card
Fundamentals & leadership quality — Minervini’s published criteria · 3/7 met
C 3/7 criteria
Separate score from the Minervini Trend Template (5/8): the Trend Template grades the price structure, this grades the company & leadership (earnings, sales, margins, RS rank). A stock can ride a clean trend while its fundamentals lag, so the two often differ by design — they are not the same checklist.
✗ EPS acceleration ≥25% QoQ -0%
✗ Revenue growth ≥20% YoY +8%
✓ Gross margin ≥30% 47%
✗ ROE ≥17% 5%
✗ RS rating ≥80 (leadership) 69
✓ Stage 2 uptrend (Weinstein) Stage 2
✓ Within 25% of 52W high -7.8%

Method Playbook

Trade it like Weinstein EXACT LEVELS · PRO
Weinstein C · Watch — The deterministic methodology check is Watch; wait for the failing or incomplete criteria to improve before the trigger can qualify.
Pivot
Pro level
Published-method rule: Use Stage 1 resistance and the rising 30-week moving average as the Stage 2 transition boundary.
Evidence: Canonical setup geometry is available with Pro.
Entry trigger
Pro level
Published-method rule: Require a Stage 2 breakout above resistance on expanding volume; avoid entries while the 30-week average is flat or falling.
Evidence: Canonical setup geometry is available with Pro.
Initial stop
Pro level
Published-method rule: Start below the breakout structure or Stage 1 support where a return to the base invalidates the Stage 2 transition.
Evidence: Canonical setup geometry is available with Pro.
Trail
Rule-based
Published-method rule: Trail beneath rising 30-week support or later higher swing lows while Stage 2 remains intact.
Evidence: Planned management rule; no stored stop or broker order is changed automatically.
Exit / invalidation
Pro level
Published-method rule: Exit on a decisive 30-week support failure or a Stage 3/Stage 4 transition; never treat a failed Stage 2 break as healthy consolidation.
Evidence: Canonical setup geometry is available with Pro.
Deterministic educational plan, not a recommendation. No order or stop is changed automatically. Method and sources →

Pattern Analysis

0 setup score
RS Score 69
Trend template 5/8
Why This Setup?
The Universal Edge Check · context only

What the setup still has going for it, recorded for later. The verdict above stands — these principles do not overrule it.

1/7 universals met
  • A relative-strength leader — not met RS rank 32 — laggard
  • Clear of earnings — not met in 6 days — event risk
  • Risk is defined — not met No stop — undefined risk
  • Asymmetric reward — partly met No target set
  • Not chasing (in range) — partly met Pivot distance unknown
  • Volume confirms — partly met 1.0× average — light
  • In a confirmed uptrend — met Stage 2 · Trend template 5/8
Why these seven? → The Universal Edge

Minervini Trend Template

5/8

Grades the price structure — moving-average stacking, distance from the 52-week high/low, and relative strength above the ≥70 uptrend bar. This is the technical trend check; the company's fundamentals and ≥80 RS leadership are scored separately in the Grade Card.

Price above SMA 150 & 200 $196.39 vs SMA150 $164.78 / SMA200 $169.85
SMA 150 above SMA 200 SMA150 $164.78 vs SMA200 $169.85
SMA 200 trending up Slope -1.05 over 20 days
SMA 50 above SMA 150 & 200 SMA50 $185.63
Price above SMA 50 $196.39 vs SMA50 $185.63
30%+ above 52-week low +40.2% from $140.11
Within 25% of 52-week high -7.8% from $213.08
RS score above 70 RS 69

Fundamentals

52W Range
77%
Mkt Cap SEC
53.5B
EPS QoQ
-0%
Rev YoY
+8%
ROE
5%
Gross Margin
47%
D/E
0.76
EPS TTM
$5.82
P/E TTM
33.7x
Float
272M
Insider
No Buy

Company

Company profile
Becton, Dickinson and Company
BDX · NYSE · Health Technology · Medical Specialties

Scan History

20× streak
Oct 23: 78 (Darvas Box)Oct 23: 86 (Cup & Handle)Oct 26: 82 (Trend Only)Oct 27: 0 (watchlist_candidate)0
Oct 27
watchlist_candidate
0
Oct 26
Trend Only ✓ Gate
82 0.0%
Oct 23
Cup & Handle ✓ Gate
86 -1.3%
Oct 23
Darvas Box ✓ Gate
78 -1.3%

Latest News

Headlines for BDX
Loading headlines…

Get the full picture on BDX

Pro members see entry/stop/target levels, R:R ratios, intraday alerts, and every setup detected across 500+ symbols daily.

Start 7-Day Free Trial